Compare Baxter International Inc (BAX) vs Salesforce Inc (CRM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Baxter International Inc vs Salesforce Inc — how do they compare? Baxter International Inc trades at $21.78 (market cap $11.26B), while Salesforce Inc trades at $168.39 (market cap $137.23B). The key difference: Salesforce Inc is far larger — about 12.2× Baxter International Inc's market cap, and Salesforce Inc pays the higher dividend (1.05%). Which is the better fit depends on your goals.
| BAX | CRM | |
|---|---|---|
Market Cap | $11.26B | $137.23B |
Sector | Health | Technology |
52-Week High | $29.22 | $270.25 |
52-Week Low | $15.80 | $150.12 |
Enterprise Value | $18.93B | $167.28B |
Dividend Yield | 0.92% | 1.05% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Baxter International (BAX) trades at $22.57, down 0.22% on the day, with mixed technical signals showing a bullish moving average trend but neutral oscillators. The company reported Q1 2026 earnings beat with $0.36 EPS versus $0.31 expected, though net income margin remains negative at -9.7%. Recent news highlights upcoming Q2 earnings call and sustainability initiatives, while analyst consensus sits at $22.67 price target with 42% buy ratings.
BAX faces fundamental challenges with negative profitability metrics and volatile cash flow, but valuation appears reasonable with P/S of 1.02. The stock offers potential upside to analyst targets if operational improvements materialize, though investors must weigh high debt levels and inconsistent earnings performance against turnaround prospects in the medical technology sector.
Salesforce (CRM) trades at $171.22, up 4.84% today, showing strong momentum despite recent sector volatility. The stock demonstrates robust fundamentals with consistent earnings beats (Q1 2026 EPS of $3.88 vs. $3.13 expected), impressive 77.64% gross margins, and accelerating revenue growth to $37.9B in 2025. Technical indicators show bullish momentum with the current price near pivot point resistance at $170, while analyst consensus remains strongly positive with a $235.90 price target.
The outlook remains favorable given Salesforce's dominant market position, AI-driven growth initiatives, and improving profitability. Key risks include sector-wide software selloffs, AI competition, and macroeconomic sensitivity. With 76.84% analyst buy ratings and strong institutional support, the stock appears undervalued relative to growth prospects despite near-term volatility concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Baxter International Inc
Baxter offers a variety of medical instruments and supplies to caregivers. It enhanced its portfolio of hospital-focused offerings by acquiring Hillrom in late 2021. Legacy Baxter offers tools to help patients with acute and chronic kidney failure. It also sells a variety of injectable therapies for use in care settings, such as IV pumps, and administrative sets.
Read more on BAX →About Salesforce Inc
Salesforce Inc provides enterprise cloud computing solutions. The company offers customer relationship management technology that brings companies and customers together. Its Customer 360 platform helps the group to deliver a single source of truth, connecting customer data across systems, apps, and devices to help companies sell, service, market, and conduct commerce. It also offers Service Cloud for customer support, Marketing Cloud for digital marketing campaigns, Commerce Cloud as an e-commerce engine, the Salesforce Platform, which allows enterprises to build applications, and other solutions, such as MuleSoft for data integration.
Read more on CRM →
